MedTrace Logo

Body PSOriasis: Long-term Relapse CONTROL

NCT03402828 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 764

Last updated 2021-03-16

No results posted yet for this study

Summary

This non-interventional study of real-life clinical practice strategies for long-term relapse control in patients with psoriasis vulgaris is planned to enroll 650 adult patients from 60-100 Russian dermatology sites and follow the patients for up to 52 weeks. The study will map actual strategies and focus on patients' and dermatologists' experience with the different topicals used, including unspecified products with and without active drugs.

Conditions

  • Psoriasis Vulgaris

Interventions

DRUG

Any topical drug treatment

Any treatment strategy used to prevent relapse of psoriasis symptoms

Sponsors & Collaborators

  • LEO Pharma

    lead INDUSTRY

Principal Investigators

  • Dmitry Petrunin, MD PhD · Leo Pharmaceutical Products LLC

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-06-11
Primary Completion
2020-05-15
Completion
2020-05-15

Countries

  • Russia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03402828 on ClinicalTrials.gov